Not all these cases meet the definition of AML with BCR::ABL1 since BCR::ABL1 acts as a secondary event and is likely to confer a proliferative advantage, such as NRAS, FLT3, or KIT mutations. Here, NRAS is linked to acute myeloid leukemia.